Market For Plasma Fractionation Is Anticipated To Surpass A CAGR Of 7% Through 2031

Plasma Fractionation Market

According to Fact.MR, the plasma fractionation market is expected to register a CAGR of more than 7% along with the market size being valued at US$ 38 Bn at the end of the 2021-2031 forecast period. Rising prevalence of infectious and chronic diseases is majorly spurring expansion of the market.

As per historical trends, between 2016 and 2020, demand for plasma fractionation surged at a CAGR of 5%, closing in at a valuation of US$ 19 Bn. The impact of COVID-19 has been tremendously huge on the plasma fractionation market. Increase in respiratory problems and blood disorders has led to patients opting for plasma fractionation. Technological advancements in the plasma fractionation sector has further propelled the growth of plasma fractionation.

Prominent manufacturers are expected to capitalize on the ever-growing prospects for treating neurological disorders. Statistics suggest that these disorders have affected 450 million globally. Thus, the neurology segment for plasma fractionation is expected to witness robust growth by registering a CAGR of 7.2%

Click Here To get a Sample Report (Including Full TOC, Table & Figures):-

Key Segments Covered

  • Product

    • Immunoglobulins for Plasma Fractionation
      • Intravenous Immunoglobulins
      • Subcutaneous Immunoglobulins
    • Coagulation Factor Concentrates for Plasma Fractionation
      • Factor VIII
      • Factor IXF
      • Factor XIII
      • Prothrombin Complex Concentrate
      • Von Willebrand Factor (VWF)
      • Fibrinogen Concentrates
    • Albumin for Plasma Fractionation
    • Protease Inhibitors for Plasma Fractionation
    • Other Plasma Products for Plasma Fractionation
  • Application

    • Plasma Fractionation for Neurology
    • Plasma Fractionation for Immunology
    • Plasma Fractionation for Haematology
    • Plasma Fractionation for Critical Care
    • Plasma Fractionation for Pulmonary Applications
    • Plasma Fractionation for Other Applications
  • End User

    • Plasma Fractionation for Hospitals & Clinics
    • Plasma Fractionation for Clinical Research Laboratories
    • Plasma Fractionation for Academic Institutions

Competitive Landscape

The plasma fractionation market consists of multiple players. Innovative product offerings and new product development are key growth strategies adopted by market players.

  • CSL Behring, for instance, markets the Privigen, Carimune, Snadoglobulin and Hizentra solutions. Sanquin produces four types of plasma products using various isolation techniques: coagulation factors, protease inhibitors, immunoglobulins and albumin. The company also offers contract fractionation services.
  • Biotest AG develops, manufactures and markets plasma proteins and biotherapeutic drugs. It leads in the field of plasma collection. Biotest AG presently develops plasma proteins for Primary Immune Deficiency (PID) and various hyperimmune products. Examples of the products offered are Varitect, Cytotect CP and Albiomin.